PA
SLGN icon

PharVision Advisers’s Silgan Holdings SLGN Stock Holding History

PharVision Advisers’s Portfolio SLGN Stock Details SLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,735
Closed -$202K – 782
2025
Q2 		$202K Sell
3,735
-6,289
-63% -$332K 0.29% 204
2025
Q1 		$512K Buy
10,024
+2,490
+33% +$131K 0.71% 14
2024
Q4 		$392K Buy
+7,534
New +$402K 0.33% 86

Other funds holding SLGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PharVision Advisers's SLGN Position: Q3 2025 in Review

PharVision Advisers sold out of Silgan Holdings (SLGN) in Q3 2025, closing a stake of 3,735 shares — an estimated $202K sold.

PharVision Advisers first reported a position in SLGN in Q4 2024 and held it in 3 quarters. The position peaked at $512K in Q1 2025. 340 funds tracked by Wall St. Rank hold SLGN as of Q3 2025.

  • PharVision Advisers reported no remaining Silgan Holdings position as of Q3 2025 after selling out during the quarter.
  • PharVision Advisers sold 3,735 Silgan Holdings shares in Q3 2025, an estimated $202K.
  • PharVision Advisers first reported a position in Silgan Holdings in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Silgan Holdings position peaked at $512K in Q1 2025.
  • 340 funds tracked by Wall St. Rank held Silgan Holdings as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.